Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

20192,505 citationsJournal Articlebronze Open Access

Authors

Robert J. Motzer · Memorial Sloan Kettering Cancer Center

Konstantin Penkov · Euromedic

John B.A.G. Haanen · The Netherlands Cancer Institute

Brian I. Rini · Cleveland Clinic

Laurence Albigès · Institut Gustave Roussy

Matthew T. Campbell · The University of Texas MD Anderson Cancer Center

Balaji Venugopal

Abstract

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced renal-cell carcinoma. (Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Renal 101 ClinicalTrials.gov number, NCT02684006.).

Topics & Keywords

Renal cell carcinoma treatment Renal and related cancers Economic and Financial Impacts of Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 12, pp. 1103-1115

DOI: 10.1056/nejmoa1816047

Field-Weighted Citation Impact: 269.65